Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 5/20 | 0.50 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | DHCR24 | Q15392 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13392661 | 1.00 | CDC25A (0.50) | CDC25ACDC25BDHCR24USP2VDR | |
| SCHEMBL6830893 | 1.00 | CDC25A (0.50) | CDC25ACDC25BDHCR24USP2VDR | |
| SCHEMBL13853984 | 0.90 | CDC25A (0.50) | CDC25ACDC25BDHCR24USP2VDR | |
| SCHEMBL6690597 | 0.87 | CDC25A (0.48) | CDC25ACDC25BDHCR24USP2VDR | |
| SCHEMBL8502677 | 0.87 | CDC25A (0.48) | CDC25ACDC25BDHCR24USP2VDR | |
| SCHEMBL13556503 | 0.83 | CDC25A (0.51) | CDC25ACDC25BDHCR24SRD5A2GPBAR1 | |
| SCHEMBL10820754 | 0.83 | CDC25A (0.51) | CDC25ACDC25BDHCR24SRD5A2GPBAR1 | |
| SCHEMBL12299291 | 0.83 | CDC25A (0.51) | CDC25ACDC25BDHCR24SRD5A2GPBAR1 | |
| SCHEMBL5070148 | 0.82 | CDC25A (0.54) | CDC25ACDC25BVDR | |
| SCHEMBL4178422 | 0.82 | CDC25A (0.42) | CDC25ACDC25BDHCR24USP2VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | BIOXELL S.P.A. (IT) | 2009-05-28 | — | — | US | claimed |
| WO-2008091686-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2008-07-31 | — | — | WO | claimed |
| EP-1924268-A2 | SYNTHESIS OF 1ALPHA-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | Bioxell S.p.a. (IT) | 2008-05-28 | — | — | EP | claimed |
| WO-2007022433-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2007-02-22 | — | — | WO | claimed |
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | BIOXELL S.P.A. (IT) | 2009-05-28 | — | — | US | disclosed |
| WO-2008091686-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2008-07-31 | — | — | WO | disclosed |
| EP-1924268-A2 | SYNTHESIS OF 1ALPHA-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | Bioxell S.p.a. (IT) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007022433-A2 | SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL | BIOXELL S.P.A. (IT) | 2007-02-22 | — | — | WO | disclosed |
| US-5939408-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS, ANTITUMOR AGENTS AND SEBACEOUS GLAND DISEASE | HOFFMAN-LA ROCHE INC. (US) | 1999-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137828-A1 | Synthesis of 1A-Fluoro-25-Hydroxy-16-23E-Diene-26,27-Bishomo-20-Epi-Cholecalciferol | CYP24A1, CYP2R1, CYP27B1 | CDC25A 2558/4885CDC25B 2734/4885DHCR24 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.